ALK and non-small cell lung carcinoma: According to the clinical practice guidelines issued by the National Comprehensive Cancer Network (NCCN), brigatinib was recommended as the first-line treatment option for the patients with ALK-positive advanced NSCLC (Benson et al., 2021).